Pfizer-BioNTech Report First Long-Term Study Results for COVID-19 Vaccine
On April 1, Pfizer-BioNTech released results from the longest study yet of their COVID-19 vaccine. In a release, the companies reported that their two-dose vaccine was 91.3% efficacious in protecting people from COVID-19 disease for up to six months. The companies’ previous data, which led to the U.S. Food and Drug Administration’s (FDA) emergency use … Read more